9. EVALUATE OF COMBINED METRONIDAZOLE PLUS IVERMECTINE EFFICACY IN THE TREATMENT FOR HUMAN DEMODICOSIS

Nguyen Ngoc Vinh1, Do Trung Dung2, Huynh Hong Quang1, Nguyen Thi Thanh Quyen1, Nguyen Duc Chinh1
1 Institute of Malariology, Parasitology, Entomology Quy Nhon
2 National Institute of Malariology, Parasitology, and Entomology

Main Article Content

Abstract

Objective: To evaluate of combined metronidazole plus ivermectine (MTZ + IVM) efficacy in treatment of human demodicosis.


Methods: A non-randomized uncontrolled trial design for evaluate of combined MTZ + IVM regimen efficacy in treatment of human demodicosis.


Results: The efficacy of combined MTZ + IVM regimen in the treatment for 80 enrolled demodicosis patients showed that significantly reduced of itching, stinging, crawling ants, and erythema/ red skin, and skin scales at points of before and after one and two months intervention; Demodex density reduced from 8.8±4.5 to 1.5 ± 1.1 and 0.6 ± 0.2/ microscope field after 1 and 2 months, respectively. The proportion of high response, moderate response, and low response were 80.3% and 88.7%; 13.2% and 5.6%; 3.9% and 1.4% in one and two months post-treatment, respectively. Non-response or treatment failure at one and two months post-treatment were 2.6% and 4.3%. Some advert events in the first ten days since drugs taken included of itching, skin burning 2 (2.5%), fatigue 6 (7.5%), dizziness 2 (2.5%), abdomen pain 3 (3.8%), nausea 3 (3.8%). 


Conclusions:Combined MTZ + IVM regimen has high efficacy 80.3% and 88,7% at one and two months post-treatment, respectively.

Article Details

References

[8] Nguyễn Thị Thanh Quyên, Nguyễn Ngọc Vinh, Huỳnh Hồng Quang (2023). Đánh giá hiệu lực phác đồ phối hợp metronidazol và ivermectin trong điều trị viêm da do ký sinh trùng Demodex spp. Tạp chí Phòng chống bệnh sốt rét và
các bệnh ký sinh trùng, Vol. 125, Số 5, tr.30-40, 2023.
[9] Trần Cẩm Vân (2023). So sánh kết quả điều trị viêm da do Demodex bằng uống ivermectin kết hợp bôi metronidazol 1% với liệu pháp uống và bôi metronidazol kết hợp. Y học cộng đồng, Số Chuyên đề ký sinh trùng, Số 76, tr. 198-203.
[10] Avila MY, Martinez-Pulgarin DF, Rizo Madrid C et al., (2021). Topical ivermectin- metronidazole gel therapy in the treatment of blepharitiscaused by Demodex: A randomized clinical trial. Cont Lens Anterior Eye;44(3):101326.
[11] Gonzalez P, Gonzalez FA, Ueno K et al., (2012). Ivermectin in human medicine: An overview of the current status of its clinical applications.Curr Pharm Biotechnol, 13(6): 1103-9.
[12] Jiahua Li, Erdong Wei, Amin Reisinger, Markus Reinholz (2023). Comparison of different anti-Demodex strategies: A systematic review and meta-analysis. Dermatology, 239(1):12-31.
[13] KashifSiddiqui, LindaSteinGold, JapinderGill (2016). The efficacy, safety, and tolerability of ivermectin compared with current topical treatments for the inflammatory lesions of rosacea: A network meta-analysis. Springer Plus (2016); 5:1151
[14] NS Lam, X Long , RC Griffin, JCG Doery, F Lu (2019). Human demodicidosis and the current treatment options. Hong Kong J. Dermatol. Venereol. (26):10-17
[15] McClellan KJ, Noble Set al.,(2000). Topical metronidazole: A review of its use in rosacea. Am J Clin Dermatol,1(3):191-9.
[16] Salem DA, El-Shazly A, Nabih N, El-Bayoumy Yet al., (2013). Evaluation of the efficacy of oral ivermectin in comparison with ivermectin-metronidazole combined therapy in the treatment of ocular and skin lesions of Demodex folliculorum. Int J Infect Dis, 17(5):343-347.
[17] Taieb A, Ortonne JP et al., (2015). Superiority of ivermectin 1% cream over metronidazole 0.75% cream in treating inflammatory lesions of rosacea: A randomized, investigator-blinded trial.Br J Dermatol, 172(4):1103-10.